Page 29 - EFH223

phase 3 trial. Lancet Oncol. 2020; 21(11): 1.465-1.477
[DOI: 10.1016/S1470-2045(20)30494-0] [Epub 2020 Sep 19. PMID: 32961119].
14. Larkin J, Chiarion-Sileni V, González R, Grob JJ, Cowey CL, Lao CD, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015; 373(1): 23-34.
15. Abdel-Wahab N, Safa H, Abudayyeh A, Johnson DH, Trinh VA, Zobniw CM, et al. Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience
and a systematic review of the literature. J Immunother Cancer. 2019; 7(1): 106 [DOI: 10.1186/s40425-019-0585-1] [Erratum in: J Immunother Cancer. 2019; 7(1): 158] [PMID: 30992053; PMCID: PMC6469201].
16. Kittai AS, Oldham H, Cetnar J, Taylor M. Immune checkpoint inhibitors in organ transplant patients. J Immunother. 2017; 40(7): 277-281 [DOI: 10.1097/CJI.0000000000000180] [PMID: 28719552].
17. Ros J, Matos I, Martin-Liberal J. Immunotherapy in organ- transplanted cancer patients: efficacy and risk of organ rejection. Ann Oncol. 2019; 30(7): 1.173-1.177 [DOI: 10.1093/ annonc/mdz129] [PMID: 30977776].
18. Regalla DKR, Williams GR, Paluri RK. Immune checkpoint inhibitors in the management of malignancies in transplant recipients. Postgrad Med J. 2018; 94(1118): 704-708 [DOI: 10.1136/postgradmedj-2018-136081] [Epub 2018 Nov 13. PMID: 30425139].
19. Informe tècnic del Consell Assessor de la Medicació Hospitalària de Dispensació Ambulatòria (CAMHDA). Tractament en monoteràpia de pacients adults amb melanoma avançat (irresecable o metastàtic) [consultado el 8 de abril de 2021]. Disponible en: https://catsalut.gencat.cat/web/.content/ minisite/catsalut/proveidors_professionals/medicaments_ farmacia/harmonitzacio/informes/pembrolizumab/Informe- pembrolizumab.pdf
20. Haas L, Wiesner T, Obenauf AC. A new era of proactive melanoma therapy: hit hard, hit early. Br J Dermatol. 2018; 178(4): 817-820 [DOI: 10.1111/bjd.16347] [PMID: 29668089].
21. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN Guidelines®). Melanoma: cutaneous. v.2.2021[consultado el 8 de abril de 2021]. Disponible en: https://www.nccn.org/professionals/physician_ gls/pdf/cutaneous_melanoma.pdf
22. Riella LV, Paterson AM, Sharpe AH, Chandraker A. Role
of the PD-1 pathway in the immune response. Am J Transplant. 2012; 12(10): 2.575-2.587 [DOI: 10.1111/j.1600-6143. 2012.04224.x] [Epub 2012 Aug 17. PMID: 22900886;
PMCID: PMC3784243].
23. Johnson DB, Sullivan RJ, Menzies AM. Immune checkpoint inhibitors in challenging populations. Cancer. 2017; 123(11): 1.904-1.911 [DOI: 10.1002/cncr.30642] [Epub 2017 Feb 27. PMID: 28241095; PMCID: PMC5445005].
24. Tanaka K, Albin MJ, Yuan X, Yamaura K, Habicht A, Murayama T, et al. PDL1 is required for peripheral transplantation tolerance and protection from chronic allograft rejection. J Immunol. 2007; 179(8): 5.204-5.210 [DOI: 10.4049/jimmunol.179.8.5204] [PMID: 17911605; PMCID: PMC2291549].
25. Menzies AM, Johnson DB, Ramanujam S, Atkinson VG, Wong ANM, Park JJ, et al. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol. 2017; 28(2): 368-376
[DOI: 10.1093/annonc/mdw443] [PMID: 27687304].
26. Knoll GA, Kokolo MB, Mallick R, Beck A, Buenaventura CD, Ducharme R, et al. Effect of sirolimus on malignancy and
survival after kidney transplantation: systematic review and meta-analysis of individual patient data. BMJ. 2014; 349: g6679 [DOI: 10.1136/bmj.g6679] [Erratum in: BMJ. 2014; 349: g7543] [PMID: 25422259; PMCID: PMC4241732].
27. Arbour KC, Mezquita L, Long N, Rizvi H, Auclin E, Ni A, et al. Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer. J Clin Oncol. 2018; 36(28): 2.872-2.878 [DOI: 10.1200/JCO.2018.79.0006] [Epub 2018 Aug 20. PMID: 30125216].
caso clínico
Tratamiento con nivolumab en una paciente oncológica trasplantada
el farmacéutico hospitales n.o 223 29